Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21500583 | 0.79 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL21523908 | 0.79 | — | — | |
| SCHEMBL2343807 | 0.78 | LMNA (0.38) | ALDH1A1OPRM1SMN1; SMN2LMNATSHR | |
| SCHEMBL440297 | 0.78 | CES2 (0.30) | SMN1; SMN2TSHRCES2LPAR1LPAR3 | |
| SCHEMBL28463852 | 0.75 | OPRM1 (0.38) | ALDH1A1OPRM1SMN1; SMN2LMNATSHR | |
| SCHEMBL21938390 | 0.72 | CES2 (0.32) | OPRM1LMNATSHRHSD17B10MEN1 | |
| SCHEMBL2328545 | 0.71 | LMNA (0.45) | ALDH1A1OPRM1SMN1; SMN2LMNATSHR | |
| SCHEMBL26064066 | 0.70 | CES2 (0.31) | LMNATSHRCES2LPAR1LPAR3 | |
| SCHEMBL24248160 | 0.70 | CES2 (0.32) | HSD17B10MEN1KMT2ACES2LPAR1 | |
| SCHEMBL18882261 | 0.70 | MEN1 (0.33) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457623-B1 | Process for the preparation of Lubiprostone and intermediates thereof | CHIROGATE INTERNATIONAL INC. (TW) | 2019-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457623-B1 | Process for the preparation of Lubiprostone and intermediates thereof | PTGIS, PTGIR, SQLE | ALDH1A1 1683/4885OPRM1 2810/4885SMN1; SMN2 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.